ALK and inflammatory myofibroblastic tumor: According to the NCCN Guidelines (Version 2.2023), ALK inhibitors – crizotinib, ceritinib, brigatinib, lorlatinib, and alectinib – are approved as first-line therapies for IMT cases with ALK rearrangements.[48] Several studies have reported that ALK inhibitors can be used to treat recurrent or refractory IMT.